- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07930364
Wearable HRV Biofeedback for Stress in Dementia Caregivers (CARE-COHERENCE)
Low-cost Wearable Heart Rate Variability Biofeedback as a Nurse-led Intervention to Reduce Stress in Informal Caregivers of People With Dementia: a Prospective Controlled Non-randomized Interventional Trial
This study will evaluate whether a nurse-led heart rate variability (HRV) biofeedback programme supported by a low-cost wearable sensor reduces autonomic dysregulation and perceived stress in informal caregivers of people with dementia. Participants will be prospectively allocated, without randomization, at the day-care-centre level. Before enrolment, the six centres will be characterised according to centre size, estimated number of eligible caregivers and expected recruitment volume, and arranged into three approximately matched pairs. One centre in each pair will implement CARE-COHERENCE and the other will serve as a concurrent comparison centre under a pre-specified operational implementation plan. Follow-up will continue for 12 months.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Approximately 100 informal caregivers of older people with dementia attending one of six participating day-care centres will be enrolled. The intervention group will receive an 8-week HRV-biofeedback programme in addition to usual caregiver support. The comparison group will receive usual caregiver support during the 12-month study period and will be offered access to programme materials after completion of the final assessment. The primary outcome is change in resting root mean square of successive differences (RMSSD) from baseline to 6 months. Perceived stress is the key secondary outcome. Assessments occur at baseline, 8 weeks, 6 months and 12 months.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Lucia Lavín Alconero
- Phone Number: +34 942203389
- Email: lucia.lavin@idival.org
Study Locations
-
-
Cantabria
-
Santander, Cantabria, Spain
- Recruiting
- Hospital Universitario Marqués de Valdecilla
-
Contact:
- Carmen Maria Sarabia Cobo
- Phone Number: +34 942203389
- Email: sarabiac@unican.es
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult (18 years or older) self-identified informal, unpaid caregiver of an older person with a clinical diagnosis of dementia attending one of the participating day-care centers.
- Providing an average of at least 28 hours of unpaid care per week for a minimum of 3 months.
- Able to understand study procedures and provide written informed consent.
- Able to use a smartphone and a simple wearable device, independently or with brief study support.
Exclusion Criteria:
- Persistent or clinically significant cardiac arrhythmia preventing reliable interbeat-interval analysis.
- Pacemaker-dependent rhythm or another condition that, in the investigator's judgment, precludes valid heart rate variability assessment.
- Current participation in formal heart rate variability biofeedback or structured resonance-frequency breathing training, or equivalent training within the previous 3 months.
- Severe uncontrolled psychiatric illness or cognitive impairment precluding informed consent or meaningful participation.
- Concurrent enrollment in another structured stress-reduction intervention trial.
- Note: use of heart rate-modifying medication, including beta-blockers, is not an exclusion criterion. Medication use is documented prospectively and considered in prespecified sensitivity analyses.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: CARE-COHERENCE HRV biofeedback program
Participants receive an 8-week nurse-led heart rate variability (HRV) biofeedback program in addition to usual caregiver support. At program entry, an individual resonance frequency is determined using paced-breathing trials across a prespecified range of approximately 4.5 to 6.5 breaths per minute. The active phase comprises four weekly nurse-led sessions of approximately 60 minutes during weeks 1-4, followed by structured supported home practice during weeks 5-8. Sessions cover the physiological rationale for HRV biofeedback, paced breathing at the selected training frequency, interpretation of simple wearable feedback, management of common practice difficulties, and a brief positive-emotion self-regulation strategy. Participants are encouraged to practice approximately 10 minutes twice daily, or to reach a minimum accumulated practice target of 70 minutes per week. One booster contact occurs at month 3. |
Nurse-delivered behavioral self-regulation training combining individualized resonance-frequency paced breathing with real-time HRV feedback from a low-cost wrist- or chest-worn sensor capable of recording interbeat intervals, paired with a compatible training application. Dose: four supervised sessions of approximately 60 minutes in weeks 1-4, delivered individually or in small groups, followed by supported home practice in weeks 5-8 (target 10 minutes twice daily, or at least 70 accumulated minutes per week), plus one booster contact at month 3. Training frequency is set per participant during an initial paced-breathing assessment across approximately 4.5-6.5 breaths per minute. A brief positive-emotion self-regulation strategy is included. The device model, firmware, and application version are prespecified before recruitment and held constant where possible. Adherence is derived from device and application logs and a participant practice log.
Other Names:
|
|
No Intervention: Usual caregiver support
Participants continue to receive usual caregiver support, including routine clinical care, information, and standard services available through the participating day-care centers and other routine health and social care services. They do not receive structured resonance-frequency breathing training or HRV biofeedback from the study team at any point during the 12-month study period. After the 12-month assessment, participants in this group will be offered access to the CARE-COHERENCE educational materials and a program orientation session. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in resting RMSSD
Time Frame: Baseline and 6 months
|
Root mean square of successive differences (RMSSD) derived from a standardised resting interbeat-interval recording obtained with the study wearable sensor and processed according to a prespecified HRV analysis protocol. Higher values indicate greater vagally mediated heart rate variability. |
Baseline and 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in perceived stress (Perceived Stress Scale, PSS-10)
Time Frame: Baseline, 8 weeks, 6 months and 12 months
|
Perceived stress measured with the 10-item Perceived Stress Scale (PSS-10). Total score ranges from 0 to 40. Higher scores indicate greater perceived stress; a decrease indicates improvement. Analyzed as change from baseline and as the follow-up value adjusted for the baseline score. This is the key secondary outcome. |
Baseline, 8 weeks, 6 months and 12 months
|
|
Maintenance of resting RMSSD at 12 months
Time Frame: Baseline and 12 months
|
Root mean square of successive differences (RMSSD, in milliseconds) derived from a standardized resting interbeat-interval recording obtained with the study wearable sensor and processed with the prespecified HRV analysis pipeline. Higher values indicate greater vagally mediated heart rate variability. Assesses whether any intervention effect on the primary outcome is maintained six months after the primary endpoint. |
Baseline and 12 months
|
|
Change in caregiver burden (Zarit Burden Interview, ZBI-22)
Time Frame: Baseline, 8 weeks, 6 months and 12 months
|
Caregiver burden measured with the 22-item Zarit Burden Interview. Total score ranges from 0 to 88. Higher scores indicate greater burden; a decrease indicates improvement. |
Baseline, 8 weeks, 6 months and 12 months
|
|
Change in resting SDNN
Time Frame: Baseline, 8 weeks, 6 months and 12 months
|
Standard deviation of normal-to-normal interbeat intervals (SDNN, in milliseconds) from the same standardized resting recording used for the primary outcome. Higher values indicate greater overall heart rate variability. |
Baseline, 8 weeks, 6 months and 12 months
|
|
Change in mean resting heart rate
Time Frame: Baseline, 8 weeks, 6 months and 12 months
|
Mean heart rate in beats per minute derived from the standardized resting interbeat-interval recording. |
Baseline, 8 weeks, 6 months and 12 months
|
|
Change in well-being (WHO-5 Well-Being Index)
Time Frame: Baseline, 8 weeks, 6 months and 12 months
|
Well-being measured with the five-item WHO-5 Well-Being Index. The raw score ranges from 0 to 25 and is multiplied by 4 to give a percentage score from 0 to 100. Higher scores indicate better well-being; an increase indicates improvement. |
Baseline, 8 weeks, 6 months and 12 months
|
|
Change in anxiety and depressive symptoms (Hospital Anxiety and Depression Scale, HADS)
Time Frame: Baseline, 8 weeks, 6 months and 12 months
|
Symptoms measured with the Hospital Anxiety and Depression Scale. The HADS-Anxiety and HADS-Depression subscales are reported separately; each ranges from 0 to 21. Higher scores indicate more severe symptoms; a decrease indicates improvement. |
Baseline, 8 weeks, 6 months and 12 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Carmen Sarabia Cobo, University of Cantabria
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CARE-COHERENCE
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
De-identified individual participant data underlying the results reported in the primary publication, together with the data dictionary, may be made available to qualified researchers whose proposed use has been approved by the study team. Data will be shared subject to a data-sharing agreement, applicable ethics committee requirements, and EU General Data Protection Regulation and Spanish data-protection law. Requests should be addressed to the corresponding author.
IPD Sharing Time Frame
Beginning 6 months after publication of the primary results report, with no specified end date.
IPD Sharing Access Criteria
Requests from qualified researchers with a methodologically sound proposal, reviewed by the study team, and subject to a signed data-sharing agreement and to applicable ethics and EU/Spanish data-protection requirements. Requests should be sent to the corresponding author.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.